<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Eur J Pediatr</journal-id>
      <journal-title>European Journal of Pediatrics</journal-title>
      <issn pub-type="ppub">0340-6199</issn>
      <issn pub-type="epub">1432-1076</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17187257</article-id>
      <article-id pub-id-type="pmc">1820762</article-id>
      <article-id pub-id-type="publisher-id">354</article-id>
      <article-id pub-id-type="doi">10.1007/s00431-006-0354-2</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Paper</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Manea</surname>
            <given-names>Minola</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kristoffersson</surname>
            <given-names>AnnCharlotte</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tsai</surname>
            <given-names>Han-Mou</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zhou</surname>
            <given-names>Wenhua</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Winqvist</surname>
            <given-names>Ingemar</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Oldaeus</surname>
            <given-names>G&#xF6;ran</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Billstr&#xF6;m</surname>
            <given-names>Rolf</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bj&#xF6;rk</surname>
            <given-names>Peter</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Holmberg</surname>
            <given-names>Lars</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Karpman</surname>
            <given-names>Diana</given-names>
          </name>
          <address>
            <phone>+46-46-2220747</phone>
            <fax>+46-46-2220748</fax>
            <email>Diana.Karpman@med.lu.se</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Pediatrics, Clinical Sciences Lund, Lund University, 221 84 Lund, Sweden </aff>
        <aff id="Aff2"><label>2</label>Division of Hematology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY USA </aff>
        <aff id="Aff3"><label>3</label>Department of Hematology, Lund University Hospital, Lund, Sweden </aff>
        <aff id="Aff4"><label>4</label>Department of Pediatrics, L&#xE4;nssjukhuset Ryhov, J&#xF6;nk&#xF6;ping, Sweden </aff>
        <aff id="Aff5"><label>5</label>Department of Hematology, K&#xE4;rnsjukhuset, Sk&#xF6;vde, Sweden </aff>
        <aff id="Aff6"><label>6</label>Department of Medicine, Malm&#xF6; University Hospital, Malm&#xF6;, Sweden </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>12</month>
        <year>2006</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2007</year>
      </pub-date>
      <volume>166</volume>
      <issue>3</issue>
      <fpage>249</fpage>
      <lpage>257</lpage>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>9</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>10</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer-Verlag 2006</copyright-statement>
      </permissions>
      <abstract>
        <p>The activity of ADAMTS13, the von Willebrand factor cleaving protease, is deficient in patients with thrombotic thrombocytopenic purpura (TTP). In the present study, the phenotype of ADAMTS13 in TTP and in normal plasma was demonstrated by immunoblotting. Normal plasma (<italic>n</italic>&#x2009;=&#x2009;20) revealed a single band at 190&#xA0;kD under reducing conditions using a polyclonal antibody, and a single band at 150&#xA0;kD under non-reducing conditions using a monoclonal antibody. ADAMTS13 was not detected in the plasma from patients with congenital TTP (<italic>n</italic>&#x2009;=&#x2009;5) by either antibody, whereas patients with acquired TTP (<italic>n</italic>&#x2009;=&#x2009;2) presented the normal phenotype. Following immunoadsorption of immunoglobulins, the ADAMTS13 band was removed from the plasma of the patients with acquired TTP, but not from that of normal individuals. This indicates that ADAMTS13 is complexed with immunoglobulin in these patients. The lack of ADAMTS13 expression in the plasma from patients with hereditary TTP may indicate defective synthesis, impaired cellular secretion, or enhanced degradation in the circulation. This study differentiated between normal and TTP plasma, as well as between congenital and acquired TTP. This method may, therefore, be used as a complement in the diagnosis of TTP.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>ADAMTS13</kwd>
        <kwd>von Willebrand factor</kwd>
        <kwd>Thrombotic thrombocytopenic purpura</kwd>
        <kwd>Immunoblotting</kwd>
        <kwd>Plasma</kwd>
        <kwd>von Willebrand factor cleaving protease</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2007</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Von Willebrand factor (VWF) is a glycoprotein that plays a key role in the primary hemostatic process by inducing platelet adhesion and aggregation at sites of vascular injury under conditions of high shear stress. The main source of circulating VWF is the endothelium, from which it is secreted in the form of ultra-large multimers (ULVWF) [<xref ref-type="bibr" rid="CR53">53</xref>]. ULVWF multimers are biologically very active [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR31">31</xref>] and, upon release, undergo processing into smaller multimers in normal individuals. This occurs on the surface of endothelial cells [<xref ref-type="bibr" rid="CR10">10</xref>]. VWF defects may potentially lead to both bleeding and thrombotic disorders: defective VWF secretion, intravascular clearance, multimer assembly, or increased proteolytic degradation may lead to different types of von Willebrand disease. On the other hand, dysfunctional VWF proteolysis may lead to the thrombotic disorder thrombotic thrombocytopenic purpura (TTP) [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
      <p>TTP is a thrombotic microangiopathy (TMA) characterized by microangiopathic hemolytic anemia, thrombocytopenia, fever, neurological and renal manifestations. Chronic recurrent TTP has been associated with the presence of ULVWF in the plasma [<xref ref-type="bibr" rid="CR30">30</xref>]. ULVWF multimers are capable of inducing increased platelet retention in children with TTP [<xref ref-type="bibr" rid="CR21">21</xref>]. These observations, along with the finding of VWF and platelet-rich (but fibrin-poor) thrombi in the microcirculation of the heart, brain, kidneys, liver, spleen, and adrenals in TTP patients [<xref ref-type="bibr" rid="CR3">3</xref>], led to the conclusion that ULVWF multimers are responsible for the disseminated platelet thrombi occurring in TTP and that their degradation to smaller VWF multimers is impaired due to the deficiency of a VWF-cleaving protease [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
      <p>Recently, the VWF-cleaving protease was purified [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR50">50</xref>] and the encoding gene sequenced, linking the protease to the ADAMTS (a disintegrin-like and metalloprotease with thrombospondin-type-1 motif) family of metalloproteases [<xref ref-type="bibr" rid="CR27">27</xref>]. The protease, named ADAMTS13, cleaves VWF at the 1605Tyr-1606Met peptide bond in the A2 domain, yielding the 140-kD and 176-kD VWF fragments present in normal plasma [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Cleavage is made possible by a conformational change in VWF due to shear stress in the circulation, which exposes the cleavage site, making it susceptible to proteolysis [<xref ref-type="bibr" rid="CR55">55</xref>]. ADAMTS13 activity is severely deficient (&lt;5% of normal plasma activity) in TTP patients [<xref ref-type="bibr" rid="CR6">6</xref>], either due to a mutation in the <italic>ADAMTS13</italic> gene in the congenital form of TTP or due to auto-antibodies in the acquired form [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Autosomal recessive hereditary TTP (also termed the Upshaw-Schulman syndrome) typically presents during the neonatal period or early childhood (&lt;10&#xA0;years of age), but may also manifest during adolescence and adulthood. Recurrent TTP episodes may occur as often as every third week. TTP recurrences are associated with cerebral vascular accidents in approximately 30% of cases, and these episodes may lead to neurological complications. Renal manifestations may be mild or may result in acute renal failure due to hemoglobinuria and TMA. About 20% of patients progress to end-stage renal failure [<xref ref-type="bibr" rid="CR28">28</xref>].</p>
      <p>Hemolytic uremic syndrome (HUS) is a similar microangiopathic disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure [<xref ref-type="bibr" rid="CR5">5</xref>]. Two forms of HUS have been described: D+ or typical (diarrhea-associated) HUS and D- or atypical (non-diarrhea-associated) HUS. D+ HUS occurs after infection with Shiga-like toxin producing bacteria, typically, enterohemorrhagic <italic>Escherichia coli</italic>. The patients are usually children presenting with abrupt onset of diarrhea, followed by the development of HUS 2&#x2013;10&#xA0;days later. A prothrombotic state precedes the acute renal failure [<xref ref-type="bibr" rid="CR8">8</xref>], but the pathogenetic mechanism is, as yet, unclear. It is assumed that bacterial virulence factors gain access to the circulation, circulate on blood cells, activate platelets, and reach the kidney, where the endothelium is injured [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. D- HUS is associated with mutations in certain complement regulatory factors, such as factor H, factor I, and membrane co-factor protein (CD46). The mutations lead to activation of the complement system on host endothelial cells [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. The resulting vascular damage may lead to the formation of thrombotic lesions in the kidneys.</p>
      <p>Although HUS patients are, typically, young children with a history of diarrhea and acute renal failure, the clinical manifestations of HUS and TTP often overlap, making differentiation between the two syndromes based solely on clinical presentation difficult. ADAMTS13 antigen levels can differentiate between HUS and TTP, as they are severely deficient in patients with congenital TTP and normal to moderately reduced in HUS [<xref ref-type="bibr" rid="CR51">51</xref>]. Assays for ADAMTS13 activity can, therefore, differentiate between TTP (congenital and acquired) and HUS [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p>
      <p>Several ADAMTS13 assays are available today based on antigen detection and activity [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], showing the presence of the protease (by enzyme-linked immunosorbent assay, ELISA) and its bioactivity in normal plasma and the lack of protease and activity in the plasma from patients with congenital TTP. These assays have also shown that patients with acquired TTP have auto-antibodies that neutralize the activity of ADAMTS13. The present study utilized a different method, immunoblotting, and two anti-ADAMTS13 antibodies against specific domains, to investigate the presence of ADAMTS13 antigen in normal plasma, TTP plasma (congenital and acquired), and in heterozygous carriers of ADAMTS13 mutations, demonstrating the presence of ADAMTS13 and its size in normal plasma, the lack thereof in congenital TTP, and auto-antibody-bound protease in acquired TTP.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Subjects</title>
        <p>Citrated plasma was available from patients with congenital (<italic>n</italic>&#x2009;=&#x2009;5) and acquired (<italic>n</italic>&#x2009;=&#x2009;2) TTP. The patient data are presented in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>. The ADAMTS13 activity level was assayed as previously described [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. 
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Clinical and laboratory data regarding thrombotic thrombocytopenic purpura (TTP) patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient no.</th><th>Sex</th><th>Age at debut </th><th>Age at sampling (years)</th><th>Current age (years)</th><th>Symptoms during episodes</th><th>No. of episodes</th><th>ADAMTS13 activity level</th><th>ADAMTS13 mutation</th><th>ADAMTS13 inhibitor </th><th>Reference</th></tr></thead><tbody><tr><td>1<sup>a</sup></td><td>M</td><td>2&#xA0;d</td><td>16</td><td>19</td><td>Jaundice, hemolytic anemia, thrombocytopenia, macroscopic hematuria, pathological urinalysis, fever, neurological symptoms, elevated serum creatinine</td><td>&gt;5</td><td>&lt;5%</td><td>4143insA<sup>bc</sup></td><td>None </td><td>[<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td>2<sup>a</sup></td><td>M</td><td>5.3&#xA0;y</td><td>17</td><td>18</td><td>Jaundice, hemolytic anemia, thrombocytopenia, fever, neurological symptoms, pathological urinalysis</td><td>&gt;5</td><td>&lt;5%</td><td>4143insA<sup>bc</sup></td><td>None</td><td>[<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td>3</td><td>F</td><td>20&#xA0;m</td><td>15</td><td>23</td><td>Hemolytic anemia, thrombocytopenia, hematuria, epileptic attacks, slightly elevated serum creatinine</td><td>&gt;5</td><td>&lt;5%</td><td>P353L<sup>d</sup>, P457L<sup>e</sup></td><td>None</td><td>[<xref ref-type="bibr" rid="CR4">4</xref>]</td></tr><tr><td>4</td><td>M</td><td>3&#xA0;y</td><td>7</td><td>9</td><td>Hemolytic anemia, thrombocytopenia, purpura, pathological urinalysis</td><td>4</td><td>&lt;5%</td><td>P671L<sup>f</sup>, 4143insA</td><td>None</td><td>[<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td>5</td><td>M</td><td>2&#xA0;d</td><td>39</td><td>39</td><td>Jaundice, hemolytic anemia, petechiae, thrombocytopenia, transitory neurological deficits and aphasia, elevated creatinine</td><td>&gt;5</td><td>&lt;5%</td><td>4143insA<sup>b</sup></td><td>None</td><td>&#x2013;</td></tr><tr><td>6</td><td>F</td><td>54&#xA0;y</td><td>70</td><td>75</td><td>Recurrent hemolytic anemia and thrombocytopenia, reduced consciousness, pathological urinalysis</td><td>&gt;5</td><td>&lt;5%</td><td>NA</td><td>0.5&#xA0;U/ml</td><td>&#x2013;</td></tr><tr><td>7</td><td>F</td><td>25&#xA0;y</td><td>42</td><td>44</td><td>Thrombocytopenia, hemolytic anemia, elevated creatinine during viral infection and pregnancy</td><td>2</td><td>&lt;5%</td><td>NA</td><td>0.2&#xA0;U/ml</td><td>&#x2013;</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Patients 1 and 2 are siblings</p><p><sup>b</sup>Patients 1, 2, and 5 are homozygous for the ADAMTS13 mutation</p><p><sup>c</sup>4143insA leads to a mutation in the second CUB domain</p><p><sup>d</sup>P353L is a mutation in the disintegrin-like domain</p><p><sup>e</sup>P457L is a mutation in the cysteine-rich domain</p><p><sup>f</sup>P671L is a mutation in the spacer domain</p><p>NA: not assayed</p></table-wrap-foot></table-wrap></p>
        <p>The study also included the parents of patients 1&#x2013;4. The parents of patients 1 and 2 are both heterozygous for the 4143insA mutation, and have protease activity levels of 20% (mother) and 50% (father), as assayed by the VWF multimeric structure analysis [<xref ref-type="bibr" rid="CR15">15</xref>]. The parents of patient 3 are heterozygous for the P353L (mother) and P457L (father) mutations, and both have 50% ADAMTS13 activity. The parents of patient 4 are heterozygous for P671L (mother) and 4143insA (father), and have 50% ADAMTS13 activity. All parents are clinically unaffected.</p>
        <p>Plasma samples from 20 healthy adult volunteers were used as controls. The study was conducted with the approval of the ethics committee of Lund University and the plasma samples were collected with the informed consent of the patients, their parents, and the controls.</p>
      </sec>
      <sec id="Sec4">
        <title>Plasma samples</title>
        <p>At the time of sampling, the patients were treated regularly with fresh frozen plasma or Octaplas (Octapharma, Stockholm, Sweden; patients 1&#x2013;5). Patient 6 was treated with plasma infusions every sixth week. Patient 7 did not receive any plasma treatment at sampling. All blood samples were obtained at least three weeks (patients 1&#x2013;4 and 6) or one week (patient 5) after the last treatment. Venous blood from patients and controls was collected, and the plasma obtained as previously described [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
      </sec>
      <sec id="Sec5">
        <title>Anti-ADAMTS13 antibodies</title>
        <p>A polyclonal anti-peptide antibody was raised in New Zealand white rabbits against a unique sequence in the second CUB domain (AA1413-1427) and affinity-purified against the peptide. Antibody specificity was tested by ELISA (plates coated with the peptide) and by immunoblotting with purified plasma ADAMTS13 [<xref ref-type="bibr" rid="CR50">50</xref>] under reducing (SDS-PAGE) and non-reducing (dot blot) conditions.</p>
        <p>The monoclonal antibody A10 [<xref ref-type="bibr" rid="CR56">56</xref>], directed against the disintegrin-like domain, was used to confirm the results of the polyclonal antibody. The polyclonal antibody reacted with ADAMTS13 under reducing (reduced by the addition of 2-mercaptoethanol to disrupt disulfide bonds in the protease) and non-reducing conditions, whereas the monoclonal antibody reacted with ADAMTS13 only under non-reducing conditions.</p>
      </sec>
      <sec id="Sec6">
        <title>Immunoblot analysis for the detection of ADAMTS13 in plasma</title>
        <p>The plasma samples (1:20) were subject to SDS-PAGE under reducing (for blotting with the polyclonal antibody) and non-reducing conditions (for blotting with the monoclonal antibody) [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Purified plasma ADAMTS13 (1:100) was used as the control for the polyclonal antibody. Immunoblotting was performed with rabbit anti-ADAMTS13 IgG 1.6&#xA0;&#x3BC;g/ml followed by goat anti-rabbit IgG HRP (DakoCytomation, Carpinteria, CA) 1:2000, or with mouse anti-ADAMTS13 IgG 0.6&#xA0;&#x3BC;g/ml followed by goat anti-mouse IgG HRP (DakoCytomation, Carpinteria, CA) 1:2000. The signal was detected by chemiluminescence. The specificity of the signal obtained with the polyclonal antibody was tested by preincubation with a 50-fold molar surplus of blocking peptide followed by immunoblotting with the blocked antibody. The specificity of the secondary antibodies was tested by omission of the primary antibodies.</p>
        <p>Immunoblotting with the polyclonal antibody revealed, in addition to ADAMTS13, two unspecific bands at 130&#xA0;kD and 170&#xA0;kD, which were identified as C3 and alpha-2-macroglobulin. These proteins were removed by incubating the plasma samples with protein A-sepharose coupled rabbit anti-C3 IgG and rabbit anti-alpha-2-macroglobulin IgG. The results obtained using the polyclonal antibody show samples from which these proteins have been removed.</p>
        <p>In order to investigate the presence of ADAMTS13-autoantibody complexes in the plasma from patients with acquired TTP, samples were passed onto protein G-sepharose (Amersham Biosciences, Buckinghamshire, UK) prior to immunoblotting. Normal plasma (<italic>n</italic>&#x2009;=&#x2009;2) was used for comparison.</p>
      </sec>
    </sec>
    <sec id="Sec7" sec-type="results">
      <title>Results</title>
      <sec id="Sec8">
        <title>Detection of ADAMTS13 in plasma samples from normal individuals</title>
        <p>Normal plasma under reducing conditions revealed a single immunoreactive band at 190&#xA0;kD when blotted against the polyclonal antibody (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a). Purified plasma ADAMTS13 showed a similar band under the same conditions (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a). The monoclonal antibody detected an immunoreactive band at 150&#xA0;kD in normal plasma under non-reducing conditions (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>b). Preincubation of the polyclonal antibody with the blocking peptide abolished the ADAMTS13 band in normal plasma (data not shown). Immunoblots in which the primary antibodies had been omitted showed no bands (data not shown).
<fig id="Fig1"><label>Fig.&#xA0;1a&#x2013;g</label><caption><p>Detection of ADAMTS13 in normal and thrombotic thrombocytopenic purpura (TTP) plasma. <bold>a</bold> The polyclonal antibody detected a single band at 190&#xA0;kD in normal plasma (NP) under reducing conditions. Purified plasma ADAMTS13 in the right lane showed a similar band. <bold>b</bold> Normal plasma under non-reducing conditions revealed an immunoreactive band at 150&#xA0;kD when blotted against the monoclonal antibody. <bold>c</bold> Immunoblotting with the polyclonal antibody revealed that patients 1&#x2013;5 with congenital TTP all lacked the ADAMTS13 band, whereas patients 6 and 7 with acquired TTP presented a normal expression pattern. Normal plasma (NP) was run on the same gel for comparison. <bold>d</bold> These results were confirmed by the monoclonal anti-ADAMTS13 antibody. <bold>e</bold> Immunoblot using the polyclonal antibody. Immunoadsorption of immunoglobulins from the plasma samples of patients 6 and 7 with acquired TTP lead to the simultaneous removal of the ADAMTS13 band, indicating that ADAMTS13 is complexed with the anti-ADAMTS13 auto-antibodies. In contrast, the ADAMTS13 band remained visible in normal plasma (NP) treated similarly. <bold>f</bold> A schematic presentation of the mechanism by which the removal of immunoglobulins leads to the removal of the ADAMTS13 antigen from the plasma of patients with acquired TTP. The plasma sample contains ADAMTS13 (<italic>filled circles</italic>), auto-antibodies to ADAMTS13 (&#x2919;), and various other plasma proteins (<italic>open circles</italic>). Immunoblotting of the plasma sample prior to the removal of immunoglobulins detects the presence of ADAMTS13 antigen. Passage of the plasma sample through a protein G-sepharose column leads to the binding and removal of all immunoglobulins from the sample. Since ADAMTS13 is bound to the anti-ADAMTS13 auto-antibodies, it is removed along with them. Immunoblotting of the flow-through shows no ADAMTS13 band. <bold>g</bold> Immunoblot with the monoclonal antibody showing a normal ADAMTS13 band in the plasma of the parents, which are all heterozygous for one mutated allele and are clinically unaffected. Lane 1: the mother of patients 1 and 2, 4143insA; lane 2: the mother of patient 3, P353L; lane 3: the father of patient 3, P457L; lane 4: the mother of patient 4, P671L; lane 5: the father of patient 4, 4143insA. Normal plasma (NP) was run on the same gel for comparison</p></caption><graphic position="anchor" xlink:href="431_2006_354_Fig1_HTML" id="MO1"/></fig></p>
      </sec>
      <sec id="Sec9">
        <title>Detection of ADAMTS13 in plasma samples from TTP patients</title>
        <p>The plasma samples from all patients with congenital TTP, regardless of the mutation, lacked the ADAMTS13 band (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>c). Patients 6 and 7 with acquired TTP revealed the same ADAMTS13 protein expression pattern as the controls (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>c). These results were obtained using both the polyclonal (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>c) and the monoclonal antibody (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>d). When immunoadsorption of plasma immunoglobulins was carried out prior to immunoblotting, the ADAMTS13 band remained visible in normal plasma, but was completely removed from the samples of the patients with acquired TTP (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>e), probably due to its association with the immunoglobulin inhibitor.</p>
      </sec>
      <sec id="Sec10">
        <title>Detection of ADAMTS13 in the parents of the TTP patients</title>
        <p>The parents of the TTP patients are all carriers of one <italic>ADAMTS13</italic> mutation and one normal allele. All parents presented a normal ADAMTS13 phenotype using both the polyclonal (data not shown) and the monoclonal antibody (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>g).</p>
      </sec>
    </sec>
    <sec id="Sec11" sec-type="discussion">
      <title>Discussion</title>
      <p>In the present study, we detected ADAMTS13 in plasma using a polyclonal and a monoclonal antibody. This assay was capable of distinguishing TTP patients from normal individuals, as well as differentiating between congenital and acquired TTP. Plasma from the patients with congenital TTP lacked the ADAMTS13 antigen. In contrast, the plasma of patients with acquired TTP expressed a normal ADAMTS13 phenotype.</p>
      <p>Previous studies describing the ADAMTS13 phenotype in normal plasma by immunoblotting with other specific anti-ADAMTS13 antibodies have shown immunoreactive bands of the same molecular weight using similar conditions [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. The ADAMTS13 antigen in patients with congenital and acquired TTP has recently been shown by ELISA, demonstrating low to undetectable ADAMTS13 levels in patients with congenital TTP [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR38">38</xref>] and decreased, but mostly detectable, levels in patients with acquired TTP [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. In the present study, the ADAMTS13 phenotype in TTP patients is described by immunoblotting, confirming the lack of ADAMTS13 antigen in the plasma of patients with congenital TTP and the presence of circulating complexes in acquired TTP. Furthermore, we showed that heterozygous carriers of the ADAMTS13-related mutations who, thus, have reduced ADAMTS13 bioactivity have a normal phenotype.</p>
      <p>The plasma of the patients with congenital TTP did not present the ADAMTS13 band. This may be due to altered synthesis, secretion or antigenicity, or due to increased breakdown of the protease in plasma. The fact that two antibodies directed to two different domains in ADAMTS13 were unable to detect the protease band makes altered antigenicity less likely to be the cause for the lack of the ADAMTS13 band in these patients. Previous studies have shown impaired secretion of the 4143insA (patients 1, 2, 4, and 5) [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR44">44</xref>] and P353L (patient 3) [<xref ref-type="bibr" rid="CR42">42</xref>] mutants from cells, thus, indicating that the protease may accumulate intracellularly, at least in some patients with congenital TTP. This may be due to a missing cell sorting signal, as in the case of 4143insA [<xref ref-type="bibr" rid="CR44">44</xref>] or due to conformational changes in the protein, impairing its secretion. Similar findings regarding two other ADAMTS13 mutations, V88M and G239V, have been recently reported [<xref ref-type="bibr" rid="CR34">34</xref>]. A total lack of ADAMTS13 activity in the plasma is thought to be incompatible with life [<xref ref-type="bibr" rid="CR27">27</xref>], thus, the patients may have very low amounts of ADAMTS13 activity in their plasma, which we were unable to detect with this method.</p>
      <p>The patients with acquired TTP presented with a normal ADAMTS13 band, which is consistent with the fact that ADAMTS13 protease genotype and expression are normal, but their activity is lower, due auto-antibodies [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. The finding that the immunoadsorption of immunoglobulins from the plasma of the patients with acquired TTP also led to the removal of the ADAMTS13 antigen from their samples indicates that the protease is complexed with the auto-antibodies in the circulation of these patients, and that this occurs even during clinical remission.</p>
      <p>The majority of the ADAMTS13 assays available today detect ADAMTS13 activity levels in plasma (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). This is performed either by detecting the VWF products resulting from ADAMTS13 cleavage (assays 1&#x2013;5) or by measuring the residual VWF activity (assays 6&#x2013;7). The VWF substrate utilized in these assays may be high molecular weight VWF (plasma-derived or recombinant; assays 1&#x2013;4) or VWF domains or short synthetic peptides (assay 5). Two multicenter studies evaluating methods 1, 3&#x2013;5, and 6&#x2013;7 showed that all assays were able to detect severely ADAMTS13-deficient plasma samples and indicated that methods 1, 6, and 7 were the most consistent and reliable methods [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. A recent smaller study evaluating the FRETS-VWF73 method (assay 5) showed that this is a reliable assay which provides results in good accordance with other methods [<xref ref-type="bibr" rid="CR26">26</xref>]. 
<table-wrap id="Tab2"><label>Table&#xA0;2</label><caption><p>ADAMTS13 assays</p></caption><table frame="hsides" rules="groups"><thead><tr><th>ASSAY</th><th>PRINCIPLE</th><th>REFERENCE</th></tr></thead><tbody><tr><td colspan="3"><bold>Detection of ADAMTS13 activity</bold></td></tr><tr><td colspan="3"><italic>Detection of VWF cleavage products</italic></td></tr><tr><td> 1. VWF multimer structure analysis</td><td>Detection of the breakdown of high-molecular-weight VWF</td><td>[<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr><td> 2. Immunoblotting of VWF </td><td>Detection of cleavage products of native VWF or recombinant VWF domains</td><td>[<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td> 3. IRMA</td><td>Detection of VWF cleavage products</td><td>[<xref ref-type="bibr" rid="CR32">32</xref>]</td></tr><tr><td> 4. Flow assay</td><td>Detection of the breakdown of ULVWF-platelet strings attached to endothelial cells</td><td>[<xref ref-type="bibr" rid="CR1">1</xref>]</td></tr><tr><td> 5. Various methods using VWF domains or short synthetic VWF  peptides as the substrate, such as the FRETS-VWF73 assay</td><td>Detection of cleavage products of the VWF domains or VWF peptides</td><td>[<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR59">59</xref>&#x2013;<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td><italic>Detection of VWF residual activity</italic></td><td/><td/></tr><tr><td> 6. Collagen binding</td><td>Detection of VWF binding to collagen; binding correlates to VWF multimer size</td><td>[<xref ref-type="bibr" rid="CR17">17</xref>]</td></tr><tr><td> 7. Ristocetin cofactor activity</td><td>Detection of platelet aggregates; VWF ability to induce platelet aggregates in the presence of ristocetin correlates to multimer size</td><td>[<xref ref-type="bibr" rid="CR7">7</xref>]</td></tr><tr><td colspan="3"><bold>Detection of ADAMTS13 antigen and auto-antibodies</bold></td></tr><tr><td> 8. ELISA</td><td>Detection of ADAMTS13 antigen or anti-ADAMTS13 auto-antibodies</td><td>[<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td> 9. Immunoblotting</td><td>Detection of anti-ADAMTS13 auto-antibodies</td><td>[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td> 10. Present assay (immunoblotting)</td><td>Detection of ADAMTS13 antigen and size and (indirectly) of auto-antibodies</td><td>&#x2013;</td></tr><tr><td colspan="3"><bold>Mutation analysis</bold></td></tr><tr><td> 11. PCR</td><td>Detection of mutations in the <italic>ADAMTS13</italic> gene</td><td>[<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr></tbody></table><table-wrap-foot><p>IRMA: immunoradiometric assay; FRET: fluorescence resonance energy transfer; FRETS-VWF73: a 73-amino-acid-long synthetic peptide which provides a minimal substrate for ADAMTS13 [<xref ref-type="bibr" rid="CR24">24</xref>] that has been made fluorogenic; PCR: polymerase chain reaction</p></table-wrap-foot></table-wrap></p>
      <p>Few recent studies have shown that ADAMTS13 antigen was detectable in plasma by ELISA (assay 8 in Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>). ELISA assays are a valuable complement to the ADAMTS13 activity assays, and offer a fast analysis of the ADAMTS13 antigen levels in plasma samples using antibodies directed to ADAMTS13. These assays are able to distinguish ADAMTS13-deficient TTP plasma from normal plasma samples. Other methods are capable of detecting anti-ADAMTS13 auto-antibodies (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>, assays 8&#x2013;9). Mutational analysis can be carried out by polymerase chain reaction (PCR) in order to detect mutations in the <italic>ADAMTS13</italic> gene (assay 11 in Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>).</p>
      <p>In the present study, we developed a qualitative, semi-quantitative assay capable of detecting ADAMTS13 antigen and anti-ADAMTS13 auto-antibodies in plasma and, thus, distinguishing between TTP and normal plasma, as well as distinguishing between congenital and acquired TTP. All patients with congenital TTP, regardless of their ADAMTS13 mutations, presented with undetectable levels of ADAMTS13 antigen, whereas patients with acquired TTP presented a normal phenotype. Heterozygous carriers of ADAMTS13 mutations also revealed a normal ADAMTS13 antigen band. Although not a quantitative method like the above-mentioned ELISA assays, the present assay offers the advantage of not only demonstrating the presence or absence of ADAMTS13 antigen, but also the molecular size of ADAMTS13 present in plasma samples. Furthermore, this assay was able to show the presence of anti-ADAMTS13 antibodies indirectly by performing immunoadsorption of plasma immunoglobulins prior to immunoblotting. In conclusion, this assay is able to distinguish between normal and TTP plasma, and also between congenital and acquired TTP. It is easy to perform and can be used at any hospital laboratory routinely using SDS-PAGE electrophoresis and immunoblotting, and offers a complement to existing ADAMTS13 methods in the diagnosis of TTP.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>The authors thank Professor M. Furlan, Central Hematology Laboratory, Inselspital, University of Bern, Switzerland, for initially performing the ADAMTS13 protease activity assays on patients 1, 2, and 3. We also thank Drs. Y. Fujimura and H. Hiura for providing us with their monoclonal (A10) mouse anti-ADAMTS13 antibody.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rice</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>J-F</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nolasco</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bernardo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Moake</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of ADAMTS-13 von Willebrand factor-cleaving metalloprotease activity using a rapid endothelial cell surface-based assay in two chronic relapsing TTP patients receiving plasma infusion</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>100</volume>
          <fpage>684a</fpage>
        </citation>
        <citation citation-type="display-unstructured">Amar S, Rice L, Dong J-F, Chow T, Nolasco L, Bernardo A, Baker KR, Moake JL (2002) Evaluation of ADAMTS-13 von Willebrand factor-cleaving metalloprotease activity using a rapid endothelial cell surface-based assay in two chronic relapsing TTP patients receiving plasma infusion. Blood 100:684a </citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arya</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Anvari</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Romo</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Cruz</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>J-F</given-names>
            </name>
            <name>
              <surname>McIntire</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Moake</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Lopez</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>99</volume>
          <issue>11</issue>
          <fpage>3971</fpage>
          <lpage>3977</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2001-11-0060</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Arya M, Anvari B, Romo GM, Cruz MA, Dong J-F, McIntire LV, Moake JL, Lopez JA (2002) Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 99(11):3971&#x2013;3977 <pub-id pub-id-type="pmid">12010796</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Asada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sumiyoshi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Suzumiya</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kaketani</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen</article-title>
          <source>Thromb Res</source>
          <year>1985</year>
          <volume>38</volume>
          <issue>5</issue>
          <fpage>469</fpage>
          <lpage>479</lpage>
          <pub-id pub-id-type="doi">10.1016/0049-3848(85)90180-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K (1985) Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 38(5):469&#x2013;479 <pub-id pub-id-type="pmid">2861671</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Assink</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Schiphorst</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Allford</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Karpman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Etzioni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Brichard</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Monnens</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Heuvel</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency</article-title>
          <source>Kidney Int</source>
          <year>2003</year>
          <volume>63</volume>
          <issue>6</issue>
          <fpage>1995</fpage>
          <lpage>1999</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1523-1755.63.6s.1.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Assink K, Schiphorst R, Allford S, Karpman D, Etzioni A, Brichard B, van de Kar N, Monnens L, van den Heuvel L (2003) Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 63(6):1995&#x2013;1999 <pub-id pub-id-type="pmid">12753286</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Besbas</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Karpman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Landau</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Loirat</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Proesmans</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Remuzzi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rizzoni</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Kar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Zimmerhackl</surname>
              <given-names>LB</given-names>
            </name>
            <collab>European Paediatric Research Group for HUS</collab>
          </person-group>
          <article-title>A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders</article-title>
          <source>Kidney Int</source>
          <year>2006</year>
          <volume>70</volume>
          <issue>3</issue>
          <fpage>423</fpage>
          <lpage>431</lpage>
        </citation>
        <citation citation-type="display-unstructured">Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, van de Kar N, Zimmerhackl LB;European Paediatric Research Group for HUS (2006) A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 70(3):423&#x2013;431 <pub-id pub-id-type="pmid">16775594</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bianchi</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Robles</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Alberio</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Furlan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>L&#xE4;mmle</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>100</volume>
          <issue>2</issue>
          <fpage>710</fpage>
          <lpage>713</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2002-02-0344</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bianchi V, Robles R, Alberio L, Furlan M, L&#xE4;mmle B (2002) von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 100(2):710&#x2013;713 <pub-id pub-id-type="pmid">12091372</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>B&#xF6;hm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vigh</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Scharrer</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13)</article-title>
          <source>Ann Hematol</source>
          <year>2002</year>
          <volume>81</volume>
          <issue>8</issue>
          <fpage>430</fpage>
          <lpage>435</lpage>
          <pub-id pub-id-type="doi">10.1007/s00277-002-0502-3</pub-id>
        </citation>
        <citation citation-type="display-unstructured">B&#xF6;hm M, Vigh T, Scharrer I (2002) Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann Hematol 81(8):430&#x2013;435 <pub-id pub-id-type="pmid">12223999</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chandler</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Jelacic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Boster</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Ciol</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Watkins</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Igarashi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tarr</surname>
              <given-names>PI</given-names>
            </name>
          </person-group>
          <article-title>Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome</article-title>
          <source>N Engl J Med</source>
          <year>2002</year>
          <volume>346</volume>
          <issue>1</issue>
          <fpage>23</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa011033</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD, Watkins SL, Igarashi T, Tarr PI (2002) Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 346(1):23&#x2013;32 <pub-id pub-id-type="pmid">11777999</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cruz</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Whitelock</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>J-F</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate</article-title>
          <source>Thromb Haemost</source>
          <year>2003</year>
          <volume>90</volume>
          <issue>6</issue>
          <fpage>1204</fpage>
          <lpage>1209</lpage>
        </citation>
        <citation citation-type="display-unstructured">Cruz MA, Whitelock J, Dong J-F (2003) Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate. Thromb Haemost 90(6):1204&#x2013;1209 <pub-id pub-id-type="pmid">14652658</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dong</surname>
              <given-names>J-F</given-names>
            </name>
            <name>
              <surname>Moake</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Nolasco</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bernardo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arceneaux</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Shrimpton</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Schade</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>McIntire</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Fujikawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lopez</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>100</volume>
          <issue>12</issue>
          <fpage>4033</fpage>
          <lpage>4039</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2002-05-1401</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dong J-F, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA (2002) ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100(12):4033&#x2013;4039 <pub-id pub-id-type="pmid">12393397</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feys</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Pareyn</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Vauterin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vandeputte</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Noppe</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Ruan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Deckmyn</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Vanhoorelbeke</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences</article-title>
          <source>J Thromb Haemost</source>
          <year>2006</year>
          <volume>4</volume>
          <issue>5</issue>
          <fpage>955</fpage>
          <lpage>962</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2006.01833.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Feys HB, Liu F, Dong N, Pareyn I, Vauterin S, Vandeputte N, Noppe W, Ruan C, Deckmyn H, Vanhoorelbeke K (2006) ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost 4(5):955&#x2013;962 <pub-id pub-id-type="pmid">16689741</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fujikawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>McMullen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family</article-title>
          <source>Blood</source>
          <year>2001</year>
          <volume>98</volume>
          <issue>6</issue>
          <fpage>1662</fpage>
          <lpage>1666</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.V98.6.1662</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fujikawa K, Suzuki H, McMullen B, Chung D (2001) Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98(6):1662&#x2013;1666 <pub-id pub-id-type="pmid">11535495</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furlan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Robles</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lamie</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis</article-title>
          <source>Blood</source>
          <year>1996</year>
          <volume>87</volume>
          <issue>10</issue>
          <fpage>4223</fpage>
          <lpage>4234</lpage>
        </citation>
        <citation citation-type="display-unstructured">Furlan M, Robles R, Lamie B (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87(10):4223&#x2013;4234 <pub-id pub-id-type="pmid">8639781</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furlan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Robles</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Solenthaler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>L&#xE4;mmle</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura</article-title>
          <source>Blood</source>
          <year>1998</year>
          <volume>91</volume>
          <issue>8</issue>
          <fpage>2839</fpage>
          <lpage>2846</lpage>
        </citation>
        <citation citation-type="display-unstructured">Furlan M, Robles R, Solenthaler M, L&#xE4;mmle B (1998) Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 91(8):2839&#x2013;2846 <pub-id pub-id-type="pmid">9531594</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furlan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Robles</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Solenthaler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wassmer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sandoz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>L&#xE4;mmle</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura</article-title>
          <source>Blood</source>
          <year>1997</year>
          <volume>89</volume>
          <issue>9</issue>
          <fpage>3097</fpage>
          <lpage>3103</lpage>
        </citation>
        <citation citation-type="display-unstructured">Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, L&#xE4;mmle B (1997) Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89(9):3097&#x2013;3103 <pub-id pub-id-type="pmid">9129011</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gerritsen</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Robles</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>L&#xE4;mmle</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Furlan</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Partial amino acid sequence of purified von Willebrand factor-cleaving protease</article-title>
          <source>Blood</source>
          <year>2001</year>
          <volume>98</volume>
          <issue>6</issue>
          <fpage>1654</fpage>
          <lpage>1661</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.V98.6.1654</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gerritsen HE, Robles R, L&#xE4;mmle B, Furlan M (2001) Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 98(6):1654&#x2013;1661 <pub-id pub-id-type="pmid">11535494</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gerritsen</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>Turecek</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>L&#xE4;mmle</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Furlan</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP)</article-title>
          <source>Thromb Haemost</source>
          <year>1999</year>
          <volume>82</volume>
          <issue>5</issue>
          <fpage>1386</fpage>
          <lpage>1389</lpage>
        </citation>
        <citation citation-type="display-unstructured">Gerritsen HE, Turecek PL, Schwarz HP, L&#xE4;mmle B, Furlan M (1999) Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 82(5):1386&#x2013;1389 <pub-id pub-id-type="pmid">10595623</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cataland</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bissell</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry</article-title>
          <source>J Thromb Haemost</source>
          <year>2006</year>
          <volume>4</volume>
          <issue>2</issue>
          <fpage>333</fpage>
          <lpage>338</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2006.01758.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Jin M, Cataland S, Bissell M, Wu HM (2006) A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry. J Thromb Haemost 4(2):333&#x2013;338 <pub-id pub-id-type="pmid">16420561</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kahn</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Herwald</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Muller-Esterl</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Schmitt</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sjogren</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Truedsson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Karpman</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Contact-system activation in children with vasculitis</article-title>
          <source>Lancet</source>
          <year>2002</year>
          <volume>360</volume>
          <issue>9332</issue>
          <fpage>535</fpage>
          <lpage>541</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(02)09743-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kahn R, Herwald H, Muller-Esterl W, Schmitt R, Sjogren AC, Truedsson L, Karpman D (2002) Contact-system activation in children with vasculitis. Lancet 360(9332):535&#x2013;541 <pub-id pub-id-type="pmid">12241658</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karpman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Holmberg</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jirgard</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lethagen</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Increased platelet retention in familial recurrent thrombotic thrombocytopenic purpura</article-title>
          <source>Kidney Int</source>
          <year>1996</year>
          <volume>49</volume>
          <issue>1</issue>
          <fpage>190</fpage>
          <lpage>199</lpage>
        </citation>
        <citation citation-type="display-unstructured">Karpman D, Holmberg L, Jirgard L, Lethagen S (1996) Increased platelet retention in familial recurrent thrombotic thrombocytopenic purpura. Kidney Int 49(1):190&#x2013;199 <pub-id pub-id-type="pmid">8770967</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Karpman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lethagen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kristoffersson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Isaksson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Holmberg</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>von Willebrand factor mediates increased platelet retention in recurrent thrombotic thrombocytopenic purpura</article-title>
          <source>Thromb Haemost</source>
          <year>1997</year>
          <volume>78</volume>
          <issue>6</issue>
          <fpage>1456</fpage>
          <lpage>1462</lpage>
        </citation>
        <citation citation-type="display-unstructured">Karpman D, Lethagen S, Kristoffersson A, Isaksson C, Holmberg L (1997) von Willebrand factor mediates increased platelet retention in recurrent thrombotic thrombocytopenic purpura. Thromb Haemost 78(6):1456&#x2013;1462 <pub-id pub-id-type="pmid">9423794</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kato</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Matsuyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Isonishi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hiura</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fujimura</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity</article-title>
          <source>Transfusion</source>
          <year>2006</year>
          <volume>46</volume>
          <issue>8</issue>
          <fpage>1444</fpage>
          <lpage>1452</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1537-2995.2006.00914.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y (2006) Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 46(8):1444&#x2013;1452 <pub-id pub-id-type="pmid">16934083</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Knovich</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Craver</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matulis</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Lawson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Owen</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Simplified assay for VWF cleaving protease (ADAMTS13) activity and inhibitor in plasma</article-title>
          <source>Am J Hematol</source>
          <year>2004</year>
          <volume>76</volume>
          <issue>3</issue>
          <fpage>286</fpage>
          <lpage>290</lpage>
          <pub-id pub-id-type="doi">10.1002/ajh.20097</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Knovich MA, Craver K, Matulis MD, Lawson H, Owen J (2004) Simplified assay for VWF cleaving protease (ADAMTS13) activity and inhibitor in plasma. Am J Hematol 76(3):286&#x2013;290 <pub-id pub-id-type="pmid">15224369</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kokame</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fujimura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Miyata</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13</article-title>
          <source>Blood</source>
          <year>2004</year>
          <volume>103</volume>
          <issue>2</issue>
          <fpage>607</fpage>
          <lpage>612</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2003-08-2861</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kokame K, Matsumoto M, Fujimura Y, Miyata T (2004) VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 103(2):607&#x2013;612 <pub-id pub-id-type="pmid">14512308</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kokame</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nobe</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kokubo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Okayama</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Miyata</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay</article-title>
          <source>Br J Haematol</source>
          <year>2005</year>
          <volume>129</volume>
          <issue>1</issue>
          <fpage>93</fpage>
          <lpage>100</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2005.05420.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129(1):93&#x2013;100 <pub-id pub-id-type="pmid">15801961</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kremer Hovinga</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Mottini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>L&#xE4;mmle</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods</article-title>
          <source>J Thromb Haemost</source>
          <year>2006</year>
          <volume>4</volume>
          <issue>5</issue>
          <fpage>1146</fpage>
          <lpage>1148</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2006.01904.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kremer Hovinga JA, Mottini M, L&#xE4;mmle B (2006) Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 4(5):1146&#x2013;1148 <pub-id pub-id-type="pmid">16689773</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Nichols</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Lian</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Foroud</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>McClintick</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>McGee</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Siemieniak</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Stark</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Gruppo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sarode</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Shurin</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Chandrasekaran</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Stabler</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Sabio</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bouhassira</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>Upshaw</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Ginsburg</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>H-M</given-names>
            </name>
          </person-group>
          <article-title>Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura</article-title>
          <source>Nature</source>
          <year>2001</year>
          <volume>413</volume>
          <issue>6855</issue>
          <fpage>488</fpage>
          <lpage>494</lpage>
          <pub-id pub-id-type="doi">10.1038/35097008</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai H-M (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413(6855):488&#x2013;494 <pub-id pub-id-type="pmid">11586351</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loirat</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Veyradier</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Girma</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Ribba</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children</article-title>
          <source>Semin Thromb Hemost</source>
          <year>2006</year>
          <volume>32</volume>
          <issue>2</issue>
          <fpage>90</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="doi">10.1055/s-2006-939764</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Loirat C, Veyradier A, Girma JP, Ribba AS, Meyer D (2006) Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children. Semin Thromb Hemost 32(2):90&#x2013;97 <pub-id pub-id-type="pmid">16575683</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manuelian</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hellwage</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Meri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Caprioli</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Noris</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Heinen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jozsi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Neumann</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Remuzzi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zipfel</surname>
              <given-names>PF</given-names>
            </name>
          </person-group>
          <article-title>Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome</article-title>
          <source>J Clin Invest</source>
          <year>2003</year>
          <volume>111</volume>
          <issue>8</issue>
          <fpage>1181</fpage>
          <lpage>1190</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI200316651</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann HP, Remuzzi G, Zipfel PF (2003) Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 111(8):1181&#x2013;1190 <pub-id pub-id-type="pmid">12697737</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moake</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Rudy</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Troll</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Weinstein</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Colannino</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Azocar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Seder</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Deykin</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura</article-title>
          <source>N Engl J Med</source>
          <year>1982</year>
          <volume>307</volume>
          <issue>23</issue>
          <fpage>1432</fpage>
          <lpage>1435</lpage>
        </citation>
        <citation citation-type="display-unstructured">Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D (1982) Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307(23):1432&#x2013;1435 <pub-id pub-id-type="pmid">6813740</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moake</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Stathopoulos</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Nolasco</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Hellums</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation</article-title>
          <source>J Clin Invest</source>
          <year>1986</year>
          <volume>78</volume>
          <issue>6</issue>
          <fpage>1456</fpage>
          <lpage>1461</lpage>
        </citation>
        <citation citation-type="display-unstructured">Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD (1986) Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 78(6):1456&#x2013;1461 <pub-id pub-id-type="pmid">3491092</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Obert</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tout</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Veyradier</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fressinaud</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Girma</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF</article-title>
          <source>Thromb Haemost</source>
          <year>1999</year>
          <volume>82</volume>
          <issue>5</issue>
          <fpage>1382</fpage>
          <lpage>1385</lpage>
        </citation>
        <citation citation-type="display-unstructured">Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma JP (1999) Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 82(5):1382&#x2013;1385 <pub-id pub-id-type="pmid">10595622</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ono</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mimuro</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Madoiwa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Soejima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kashiwakura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ishiwata</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Takano</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ohmori</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Sakata</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure</article-title>
          <source>Blood</source>
          <year>2006</year>
          <volume>107</volume>
          <issue>2</issue>
          <fpage>528</fpage>
          <lpage>534</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2005-03-1087</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ono T, Mimuro J, Madoiwa S, Soejima K, Kashiwakura Y, Ishiwata A, Takano K, Ohmori T, Sakata Y (2006) Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 107(2):528&#x2013;534 <pub-id pub-id-type="pmid">16189276</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peyvandi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lavoretano</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Palla</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Valsecchi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Merati</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cristofaro</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mannuccio Mannucci</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity</article-title>
          <source>Hum Mutat</source>
          <year>2006</year>
          <volume>27</volume>
          <issue>4</issue>
          <fpage>330</fpage>
          <lpage>336</lpage>
          <pub-id pub-id-type="doi">10.1002/humu.20267</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Peyvandi F, Lavoretano S, Palla R, Valsecchi C, Merati G, De Cristofaro R, Rossi E, Mannuccio Mannucci P (2006) Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Hum Mutat 27(4):330&#x2013;336 <pub-id pub-id-type="pmid">16453338</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pimanda</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Maekawa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wind</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Paxton</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chesterman</surname>
              <given-names>CN</given-names>
            </name>
            <name>
              <surname>Hogg</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13</article-title>
          <source>Blood</source>
          <year>2004</year>
          <volume>103</volume>
          <issue>2</issue>
          <fpage>627</fpage>
          <lpage>629</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2003-04-1346</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Pimanda JE, Maekawa A, Wind T, Paxton J, Chesterman CN, Hogg PJ (2004) Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood 103(2):627&#x2013;629 <pub-id pub-id-type="pmid">14512317</pub-id></citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Proulx</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Seidman</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Karpman</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome</article-title>
          <source>Pediatr Res</source>
          <year>2001</year>
          <volume>50</volume>
          <issue>2</issue>
          <fpage>163</fpage>
          <lpage>171</lpage>
        </citation>
        <citation citation-type="display-unstructured">Proulx F, Seidman EG, Karpman D (2001) Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. Pediatr Res 50(2):163&#x2013;171 <pub-id pub-id-type="pmid">11477199</pub-id></citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Remuzzi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Galbusera</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Noris</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Canciani</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Daina</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bresin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Contaretti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Caprioli</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gamba</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ruggenenti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Perico</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mannucci</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>100</volume>
          <issue>3</issue>
          <fpage>778</fpage>
          <lpage>785</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2001-12-0166</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Remuzzi G, Galbusera M, Noris M, Canciani MT, Daina E, Bresin E, Contaretti S, Caprioli J, Gamba S, Ruggenenti P, Perico N, Mannucci PM (2002) von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 100(3):778&#x2013;785 <pub-id pub-id-type="pmid">12130486</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rieger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kremer Hovinga</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Konetschny</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Herzog</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Koller</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Remuzzi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dockal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Plaimauer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Scheiflinger</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA)</article-title>
          <source>Thromb Haemost</source>
          <year>2006</year>
          <volume>95</volume>
          <issue>2</issue>
          <fpage>212</fpage>
          <lpage>220</lpage>
        </citation>
        <citation citation-type="display-unstructured">Rieger M, Ferrari S, Kremer Hovinga JA, Konetschny C, Herzog A, Koller L, Weber A, Remuzzi G, Dockal M, Plaimauer B, Scheiflinger F (2006) Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb Haemost 95(2):212&#x2013;220 <pub-id pub-id-type="pmid">16493480</pub-id></citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rieger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mannucci</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Kremer Hovinga</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Herzog</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gerstenbauer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Konetschny</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zimmermann</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Scharrer</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Peyvandi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Galbusera</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Remuzzi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bohm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Plaimauer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>L&#xE4;mmle</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Scheiflinger</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>106</volume>
          <issue>4</issue>
          <fpage>1262</fpage>
          <lpage>1267</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2004-11-4490</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, Zimmermann K, Scharrer I, Peyvandi F, Galbusera M, Remuzzi G, Bohm M, Plaimauer B, L&#xE4;mmle B, Scheiflinger F (2005) ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 106(4):1262&#x2013;1267 <pub-id pub-id-type="pmid">15890682</pub-id></citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sadler</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>von Willebrand factor: two sides of a coin</article-title>
          <source>J Thromb Haemost</source>
          <year>2005</year>
          <volume>3</volume>
          <issue>8</issue>
          <fpage>1702</fpage>
          <lpage>1709</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2005.01369.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sadler JE (2005) von Willebrand factor: two sides of a coin. J Thromb Haemost 3(8):1702&#x2013;1709 <pub-id pub-id-type="pmid">16102036</pub-id></citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scheiflinger</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kn&#xF6;bl</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Trattner</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Plaimauer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Mohr</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Dockal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dorner</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rieger</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>102</volume>
          <issue>9</issue>
          <fpage>3241</fpage>
          <lpage>3243</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2003-05-1616</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Scheiflinger F, Kn&#xF6;bl P, Trattner B, Plaimauer B, Mohr G, Dockal M, Dorner F, Rieger M (2003) Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 102(9):3241&#x2013;3243 <pub-id pub-id-type="pmid">12855569</pub-id></citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation citation-type="other">Schneppenheim R, Angerhaus D, Obser T, Scheiflinger F, Will K, Budde U (2003) Molecular mechanisms of hereditary ADAMTS13 deficiency. Blood 102 (Abstract)</citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schneppenheim</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kremer Hovinga</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Budde</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Karpman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Brockhaus</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hrachovinova</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Korczowski</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Oyen</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rittich</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rosen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tjonnfjord</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Pimanda</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Wienker</surname>
              <given-names>TF</given-names>
            </name>
            <name>
              <surname>L&#xE4;mmle</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>A common origin of the 4143insA ADAMTS13 mutation</article-title>
          <source>Thromb Haemost</source>
          <year>2006</year>
          <volume>96</volume>
          <issue>1</issue>
          <fpage>3</fpage>
          <lpage>6</lpage>
        </citation>
        <citation citation-type="display-unstructured">Schneppenheim R, Kremer Hovinga JA, Becker T, Budde U, Karpman D, Brockhaus W, Hrachovinova I, Korczowski B, Oyen F, Rittich S, von Rosen J, Tjonnfjord GE, Pimanda JE, Wienker TF, L&#xE4;mmle B (2006) A common origin of the 4143insA ADAMTS13 mutation. Thromb Haemost 96(1):3&#x2013;6 <pub-id pub-id-type="pmid">16807643</pub-id></citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>XW</given-names>
            </name>
            <name>
              <surname>Niiya</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>XL</given-names>
            </name>
          </person-group>
          <source>Blood</source>
          <year>2006</year>
          <volume>108</volume>
          <issue>7</issue>
          <fpage>2207</fpage>
          <lpage>2215</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2006-02-002139</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Shang D, Zheng XW, Niiya M, Zheng XL (2006) Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 108(7):2207&#x2013;2215 <pub-id pub-id-type="pmid">16597588</pub-id></citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shelat</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ai</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>XL</given-names>
            </name>
          </person-group>
          <article-title>Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo</article-title>
          <source>J Thromb Haemost</source>
          <year>2006</year>
          <volume>4</volume>
          <issue>8</issue>
          <fpage>1707</fpage>
          <lpage>1717</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2006.02025.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Shelat SG, Smith P, Ai J, Zheng XL (2006) Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 4(8):1707&#x2013;1717 <pub-id pub-id-type="pmid">16879212</pub-id></citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soejima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hirashima</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Morikawa</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Nozaki</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nakagaki</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Analysis on the molecular species and concentration of circulating ADAMTS13 in blood</article-title>
          <source>J Biochem (Tokyo)</source>
          <year>2006</year>
          <volume>139</volume>
          <issue>1</issue>
          <fpage>147</fpage>
          <lpage>154</lpage>
        </citation>
        <citation citation-type="display-unstructured">Soejima K, Nakamura H, Hirashima M, Morikawa W, Nozaki C, Nakagaki T (2006) Analysis on the molecular species and concentration of circulating ADAMTS13 in blood. J Biochem (Tokyo) 139(1):147&#x2013;154 <pub-id pub-id-type="pmid">16428330</pub-id></citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>St&#xE5;hl</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Svensson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>M&#xF6;rgelin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Svanborg</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tarr</surname>
              <given-names>PI</given-names>
            </name>
            <name>
              <surname>Mooney</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Watkins</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Karpman</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome</article-title>
          <source>Blood</source>
          <year>2006</year>
          <volume>108</volume>
          <issue>1</issue>
          <fpage>167</fpage>
          <lpage>176</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2005-08-3219</pub-id>
        </citation>
        <citation citation-type="display-unstructured">St&#xE5;hl AL, Svensson M, M&#xF6;rgelin M, Svanborg C, Tarr PI, Mooney JC, Watkins SL, Johnson R, Karpman D (2006) Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood 108(1):167&#x2013;176 <pub-id pub-id-type="pmid">16514062</pub-id></citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Studt</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Bohm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Budde</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Girma</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Varadi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>L&#xE4;mmle</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods</article-title>
          <source>J Thromb Haemost</source>
          <year>2003</year>
          <volume>1</volume>
          <issue>9</issue>
          <fpage>1882</fpage>
          <lpage>1887</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1538-7836.2003.00385.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Studt JD, Bohm M, Budde U, Girma JP, Varadi K, L&#xE4;mmle B (2003) Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost 1(9):1882&#x2013;1887 <pub-id pub-id-type="pmid">12941027</pub-id></citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tripodi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chantarangkul</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bohm</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Budde</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>J-F</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Galbusera</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Girma</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Moake</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rick</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Studt</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Turecek</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Mannucci</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas</article-title>
          <source>J Thromb Haemost</source>
          <year>2004</year>
          <volume>2</volume>
          <issue>9</issue>
          <fpage>1601</fpage>
          <lpage>1609</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2004.00879.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tripodi A, Chantarangkul V, Bohm M, Budde U, Dong J-F, Friedman KD, Galbusera M, Girma JP, Moake J, Rick ME, Studt JD, Turecek PL, Mannucci PM (2004) Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2(9):1601&#x2013;1609 <pub-id pub-id-type="pmid">15333037</pub-id></citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>H-M</given-names>
            </name>
          </person-group>
          <article-title>Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion</article-title>
          <source>Blood</source>
          <year>1996</year>
          <volume>87</volume>
          <issue>10</issue>
          <fpage>4235</fpage>
          <lpage>4244</lpage>
        </citation>
        <citation citation-type="display-unstructured">Tsai H-M (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87(10):4235&#x2013;4244 <pub-id pub-id-type="pmid">8639782</pub-id></citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>H-M</given-names>
            </name>
            <name>
              <surname>Chandler</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Sarode</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hoffman</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jelacic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Habeeb</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Watkins</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Tarr</surname>
              <given-names>PI</given-names>
            </name>
          </person-group>
          <article-title>von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome</article-title>
          <source>Pediatr Res</source>
          <year>2001</year>
          <volume>49</volume>
          <issue>5</issue>
          <fpage>653</fpage>
          <lpage>659</lpage>
        </citation>
        <citation citation-type="display-unstructured">Tsai H-M, Chandler WL, Sarode R, Hoffman R, Jelacic S, Habeeb RL, Watkins SL, Wong CS, Williams GD, Tarr PI (2001) von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res 49(5):653&#x2013;659 <pub-id pub-id-type="pmid">11328948</pub-id></citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>H-M</given-names>
            </name>
            <name>
              <surname>Lian</surname>
              <given-names>EC</given-names>
            </name>
          </person-group>
          <article-title>Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura</article-title>
          <source>N Engl J Med</source>
          <year>1998</year>
          <volume>339</volume>
          <issue>22</issue>
          <fpage>1585</fpage>
          <lpage>1594</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199811263392203</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tsai H-M, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339(22):1585&#x2013;1594 <pub-id pub-id-type="pmid">9828246</pub-id></citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>H-M</given-names>
            </name>
            <name>
              <surname>Nagel</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Hatcher</surname>
              <given-names>VB</given-names>
            </name>
            <name>
              <surname>Sussman</surname>
              <given-names>II</given-names>
            </name>
          </person-group>
          <article-title>Multimeric composition of endothelial cell-derived von Willebrand factor</article-title>
          <source>Blood</source>
          <year>1989</year>
          <volume>73</volume>
          <issue>8</issue>
          <fpage>2074</fpage>
          <lpage>2076</lpage>
        </citation>
        <citation citation-type="display-unstructured">Tsai H-M, Nagel RL, Hatcher VB, Sussman II (1989) Multimeric composition of endothelial cell-derived von Willebrand factor. Blood 73(8):2074&#x2013;2076 <pub-id pub-id-type="pmid">2786433</pub-id></citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>H-M</given-names>
            </name>
            <name>
              <surname>Raoufi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Guinto</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Grafos</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ranzurmal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Greenfield</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Rand</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura</article-title>
          <source>Thromb Haemost</source>
          <year>2006</year>
          <volume>95</volume>
          <issue>5</issue>
          <fpage>886</fpage>
          <lpage>892</lpage>
        </citation>
        <citation citation-type="display-unstructured">Tsai H-M, Raoufi M, Zhou W, Guinto E, Grafos N, Ranzurmal S, Greenfield RS, Rand JH (2006) ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 95(5):886&#x2013;892 <pub-id pub-id-type="pmid">16676082</pub-id></citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>H-M</given-names>
            </name>
            <name>
              <surname>Sussman</surname>
              <given-names>II</given-names>
            </name>
            <name>
              <surname>Nagel</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
          <article-title>Shear stress enhances the proteolysis of von Willebrand factor in normal plasma</article-title>
          <source>Blood</source>
          <year>1994</year>
          <volume>83</volume>
          <issue>8</issue>
          <fpage>2171</fpage>
          <lpage>2179</lpage>
        </citation>
        <citation citation-type="display-unstructured">Tsai H-M, Sussman II, Nagel RL (1994) Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 83(8):2171&#x2013;2179 <pub-id pub-id-type="pmid">8161783</pub-id></citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Uemura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tatsumi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fujimoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Matsuyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ishikawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Iwamoto</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wanaka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fukui</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fujimura</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Localization of ADAMTS13 to the stellate cells of human liver</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>106</volume>
          <issue>3</issue>
          <fpage>922</fpage>
          <lpage>924</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2005-01-0152</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, Iwamoto TA, Mori T, Wanaka A, Fukui H, Fujimura Y (2005) Localization of ADAMTS13 to the stellate cells of human liver. Blood 106(3):922&#x2013;924 <pub-id pub-id-type="pmid">15855280</pub-id></citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>V&#xE1;radi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Schreiner</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Plaimauer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rieger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Scheiflinger</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kn&#xF6;bl</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Turecek</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>HP</given-names>
            </name>
          </person-group>
          <article-title>ADAMTS13 autoantibody detection by quantitative immunoblotting</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>102</volume>
          <issue>5</issue>
          <fpage>1932</fpage>
          <lpage>1933</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2003-05-1688</pub-id>
        </citation>
        <citation citation-type="display-unstructured">V&#xE1;radi K, Schreiner J, Plaimauer B, Rieger M, Scheiflinger F, Kn&#xF6;bl P, Turecek PL, Schwarz HP (2003) ADAMTS13 autoantibody detection by quantitative immunoblotting. Blood 102(5):1932&#x2013;1933 <pub-id pub-id-type="pmid">12930734</pub-id></citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vaziri-Sani</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Holmberg</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sj&#xF6;holm</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Kristoffersson</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Manea</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fremeaux-Bacchi</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Fehrman-Ekholm</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Raafat</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Karpman</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome</article-title>
          <source>Kidney Int</source>
          <year>2006</year>
          <volume>69</volume>
          <issue>6</issue>
          <fpage>981</fpage>
          <lpage>988</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.ki.5000155</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Vaziri-Sani F, Holmberg L, Sj&#xF6;holm AG, Kristoffersson AC, Manea M, Fremeaux-Bacchi V, Fehrman-Ekholm I, Raafat R, Karpman D (2006) Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int 69(6):981&#x2013;988 <pub-id pub-id-type="pmid">16528247</pub-id></citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whitelock</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Nolasco</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bernardo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Moake</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>J-F</given-names>
            </name>
            <name>
              <surname>Cruz</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate</article-title>
          <source>J Thromb Haemost</source>
          <year>2004</year>
          <volume>2</volume>
          <issue>3</issue>
          <fpage>485</fpage>
          <lpage>491</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2004.00601.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Whitelock JL, Nolasco L, Bernardo A, Moake J, Dong J-F, Cruz MA (2004) ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate. J Thromb Haemost 2(3):485&#x2013;491 <pub-id pub-id-type="pmid">15009467</pub-id></citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Fujikawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lian</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>McMullen</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Kulman</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>DW</given-names>
            </name>
          </person-group>
          <article-title>A rapid enzyme-linked assay for ADAMTS-13</article-title>
          <source>J Thromb Haemost</source>
          <year>2006</year>
          <volume>4</volume>
          <issue>1</issue>
          <fpage>129</fpage>
          <lpage>136</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1538-7836.2005.01677.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Wu JJ, Fujikawa K, Lian EC, McMullen BA, Kulman JD, Chung DW (2006) A rapid enzyme-linked assay for ADAMTS-13. J Thromb Haemost 4(1):129&#x2013;136 <pub-id pub-id-type="pmid">16409462</pub-id></citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhou</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>H-M</given-names>
            </name>
          </person-group>
          <article-title>An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations</article-title>
          <source>Thromb Haemost</source>
          <year>2004</year>
          <volume>91</volume>
          <issue>4</issue>
          <fpage>806</fpage>
          <lpage>811</lpage>
        </citation>
        <citation citation-type="display-unstructured">Zhou W, Tsai H-M (2004) An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations. Thromb Haemost 91(4):806&#x2013;811 <pub-id pub-id-type="pmid">15045144</pub-id></citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ADAMTS13</term>
          <def>
            <p>a disintegrin-like and metalloprotease with thrombospondin-type-1 motifs, 13</p>
          </def>
        </def-item>
        <def-item>
          <term>ELISA</term>
          <def>
            <p>enzyme-linked immunosorbent assay</p>
          </def>
        </def-item>
        <def-item>
          <term>HUS</term>
          <def>
            <p>hemolytic uremic syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>TMA</term>
          <def>
            <p>thrombotic microangiopathy</p>
          </def>
        </def-item>
        <def-item>
          <term>TTP</term>
          <def>
            <p>thrombotic thrombocytopenic purpura</p>
          </def>
        </def-item>
        <def-item>
          <term>ULVWF</term>
          <def>
            <p>ultra-large von Willebrand factor</p>
          </def>
        </def-item>
        <def-item>
          <term>VWF</term>
          <def>
            <p>von Willebrand factor</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p><italic>Grants</italic>: This study was supported by grants from the Swedish Research Council (06X-14008 to DK and 04997 to LH), Swedish Renal Foundation, Anna-Lisa and Sven-Eric Lundgren Foundation for Medical Research, Greta and Johan Kock Foundation, Crafoord Foundation, Inga and John Hains Foundation, Alfred &#xD6;sterlund Foundation, Crown Princess Lovisa&#x2019;s Society for Child Care, Thelma Zoegas Foundation, Sven Jerring Foundation, the Swedish Society of Nephrology, &#xC5;ke Wiberg Foundation, the Blood and Defence Network at Lund University, Magnus Bergvalls Foundation, and Maggie Stephens Foundation (all to DK); the Ellen Bachrach Foundation (to ACK); National Heart, Lung and Blood Institute of the NIH (R01 HL62136 and R01 HL72876 to H-MT); Sl&#xE4;ttens Ideella Barnhj&#xE4;lp (to LH).</p>
      </fn>
    </fn-group>
  </back>
</article>
</pmc-articleset>